Intelligent Bio Solutions Inc. (INBS) has initiated a validation study aimed at reducing the analysis time of its Intelligent Fingerprinting Drug Screening System from ten minutes to under three minutes. This development is pivotal as it targets the burgeoning global roadside drug testing market, projected to reach $1.62 billion by 2030. The current system already allows for sample collection in under a minute, and faster results will enhance its appeal to law enforcement agencies, which are increasingly focused on combating impaired driving.

The significance of this advancement lies in its potential to transform roadside drug testing, akin to how breathalyzers revolutionized alcohol enforcement. With the rise in drug-related incidents due to increased prescription medications and recreational drug use, law enforcement’s demand for rapid, accurate testing solutions is intensifying. By achieving a time-to-result of under three minutes, INBS could significantly increase testing throughput, allowing officers to screen more drivers efficiently, thereby improving road safety and potentially saving lives.

This shift toward accelerated testing could reshape current research paradigms and drug development timelines in the field of drug screening. Enhanced speed and efficiency may not only bolster INBS’s competitive edge in the U.S. market but also facilitate broader applications in other sectors, such as workplace testing and drug rehabilitation. As the company navigates the regulatory landscape for FDA 510(k) clearance for its system, the implications of this validation study extend beyond immediate market opportunities, potentially influencing future innovations in non-invasive testing technologies.

Source: globenewswire.com